Gapping up
In reaction to strong earnings/guidance: N/A.
M&A news: GAS +7.3% (Southern Company (SO) to Acquire AGL Resources (GAS) in $12 Billion Transaction -- AGL Resources' shareholders will be entitled to receive $66 in cash)
Other news: SPEX +22.5% (provided an update on its case involving the company's NNPT subsidiary against Huawei), OPXA +15.7% (cont strength from last week), PPHM +7% (Peregrine Pharma and AstraZeneca (AZN) form collaboration to focus on on immuno-oncology combination clinical trial), ACTS +3.1% (Action Semi to purchase for cash up to 48,000,000 of its issued and outstanding ordinary shares through a Dutch Auction Tender Offer), JOE +2.1% (tenders offer to purchase up to 16,666,666 shares of its outstanding common stock at a price of $18.00 per share), EPZM +1.1% (FDA has accepted the company's investigational new drug (IND) application for tazemetostat for the treatment of adults and pediatric patients), .
Analyst comments: N/
A
In reaction to strong earnings/guidance: N/A.
M&A news: GAS +7.3% (Southern Company (SO) to Acquire AGL Resources (GAS) in $12 Billion Transaction -- AGL Resources' shareholders will be entitled to receive $66 in cash)
Other news: SPEX +22.5% (provided an update on its case involving the company's NNPT subsidiary against Huawei), OPXA +15.7% (cont strength from last week), PPHM +7% (Peregrine Pharma and AstraZeneca (AZN) form collaboration to focus on on immuno-oncology combination clinical trial), ACTS +3.1% (Action Semi to purchase for cash up to 48,000,000 of its issued and outstanding ordinary shares through a Dutch Auction Tender Offer), JOE +2.1% (tenders offer to purchase up to 16,666,666 shares of its outstanding common stock at a price of $18.00 per share), EPZM +1.1% (FDA has accepted the company's investigational new drug (IND) application for tazemetostat for the treatment of adults and pediatric patients), .
Analyst comments: N/
A